Shares of Mesoblast Ltd (MSB.AU) are soaring, with the stock rising 8.93% during the intraday trading session.
The significant price jump follows the company's announcement on Friday that its cell therapy Ryoncil booked quarterly net revenue of $36 million, a notable increase from $30.3 million in the previous quarter. This positive earnings update has fueled investor optimism, driving the stock to its highest level in several months.